These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

58 related items for PubMed ID: 9022806

  • 21. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.
    Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, Gopalakrishnan M, Lin NH, Osinski MA, Reinhart GA, Buckley MJ, Martin RL, McDermott JS, Preusser LC, Seifert TR, Su Z, Cox BF, Decker MW, Sullivan JP.
    CNS Drug Rev; 2004; 10(2):167-82. PubMed ID: 15179445
    [Abstract] [Full Text] [Related]

  • 22. [Structural characteristics of the recognition site of cholinergic ligands of the nicotinic acetylcholine receptor from squid optic ganglia].
    Pliashkevich IuG, Demushkin VP.
    Biokhimiia; 1985 Jul; 50(7):1167-74. PubMed ID: 4041496
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. New isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates.
    Silva NM, Tributino JL, Miranda AL, Barreiro EJ, Fraga CA.
    Eur J Med Chem; 2002 Feb; 37(2):163-70. PubMed ID: 11858848
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist.
    Muro F, Iimura S, Sugimoto Y, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Matsumoto K, Satoh A, Takayama G, Taira T, Yokoyama M, Takashi T, Nakayama A, Machinaga N.
    J Med Chem; 2009 Dec 24; 52(24):7974-92. PubMed ID: 19891440
    [Abstract] [Full Text] [Related]

  • 30. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement.
    Buccafusco JJ, Jackson WJ, Terry AV, Marsh KC, Decker MW, Arneric SP.
    Psychopharmacology (Berl); 1995 Aug 24; 120(3):256-66. PubMed ID: 8524972
    [Abstract] [Full Text] [Related]

  • 31. Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist.
    Damaj MI, Creasy KR, Welch SP, Rosecrans JA, Aceto MD, Martin BR.
    Psychopharmacology (Berl); 1995 Aug 24; 120(4):483-90. PubMed ID: 8539331
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease.
    Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA.
    Psychopharmacology (Berl); 1999 Mar 24; 142(4):334-42. PubMed ID: 10229057
    [Abstract] [Full Text] [Related]

  • 34. A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.
    Setoguchi M, Iimura S, Sugimoto Y, Yoneda Y, Chiba J, Watanabe T, Muro F, Iigo Y, Takayama G, Yokoyama M, Taira T, Aonuma M, Takashi T, Nakayama A, Machinaga N.
    Bioorg Med Chem; 2013 Jan 01; 21(1):42-61. PubMed ID: 23218775
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418.
    Prendergast MA, Terry AV, Jackson WJ, Marsh KC, Decker MW, Arneric SP, Buccafusco JJ.
    Psychopharmacology (Berl); 1997 Apr 01; 130(3):276-84. PubMed ID: 9151363
    [Abstract] [Full Text] [Related]

  • 37. Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
    Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, Nelson SL, Cowart MD, Nakane M, Miller LN, Uchic ME, Terranova MA, El-Kouhen OF, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Chang R, Martino BR, Wetter JM, Marsh KC, Martin R, Darbyshire JF, Gintant G, Hsieh GC, Moreland RB, Sullivan JP, Brioni JD, Stewart AO.
    J Med Chem; 2006 Dec 14; 49(25):7450-65. PubMed ID: 17149874
    [Abstract] [Full Text] [Related]

  • 38. α6-Containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticity.
    Berry JN, Engle SE, McIntosh JM, Drenan RM.
    Neuroscience; 2015 Sep 24; 304():161-75. PubMed ID: 26210579
    [Abstract] [Full Text] [Related]

  • 39. ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice.
    Yildirim E, Connor DA, Gould TJ.
    Behav Pharmacol; 2015 Apr 24; 26(3):241-8. PubMed ID: 25426579
    [Abstract] [Full Text] [Related]

  • 40. Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats.
    Lee AM, Arreola AC, Kimmey BA, Schmidt HD.
    Behav Brain Res; 2014 Nov 01; 274():168-75. PubMed ID: 25128791
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.